The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
This is just a glimpse of the insights available to CivicScience clients. Want to see the full picture? Let’s talk. As the ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of ...
Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...
For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...
Italian Deli, which includes salami, bacon and more, is available through April 29; c-store chain also debuts King's Hawaiian ...
The Dow, S&P 500, and Nasdaq are gaining Tuesday as the stock market digests a report on producer price inflation and rising bond yields.
Ozempic, approved for Type 2 diabetes, has gained fame for its weight-loss properties, especially among celebrities. Despite its rising popularity, ex ...
The company also dropped a clue about who is -- or isn't -- winning market share in GLP-1 drug sales. In a press release this ...
Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The ...
Kentucky leads the nation with 21 prescriptions per 1,000 residents, reflecting its 36.5% obesity rate and robust healthcare access.